Medite Cancer Diagnostics, Inc. - MDIT - Fundamentals

Feel free to try out our engine!Whenever you're ready, pick a plan!

Best Investments/trading ideas for the weekJoin our free webinar on September23,2026.

Insider Tracker is here!

‌
‌

‌

Let's get started...

‌

Breakdown	2015 12/31	2016 12/31	2017 12/31	TTM
REVENUE	10	9	7	--	📊
Revenue Growth (1Y)	--	-6.56%	-26.25%	--	📊
Revenue Growth (5Y)	--	--	--	--	📊
Revenue Growth (10Y)	--	--	--	--	📊
Cost of Revenue	6	6	7	--	📊
Cost of Revenue Growth (1Y)	--	-7.01%	+19.27%	--	📊
Cost of Revenue Growth (5Y)	--	--	--	--	📊
Cost of Revenue Growth (10Y)	--	--	--	--	📊
Gross Profit	4	3	-0	--	📊
Gross Profit Growth (1Y)	--	-5.79%	-103.83%	--	📊
Gross Profit Growth (5Y)	--	--	--	--	📊
Gross Profit Growth (10Y)	--	--	--	--	📊
Operating Expenses	4	5	6	--	📊
Operating Expenses Growth (1Y)	--	+20.17%	+25.05%	--	📊
Operating Expenses Growth (5Y)	--	--	--	--	📊
Operating Expenses Growth (10Y)	--	--	--	--	📊
Sell General Administrative	3	4	5	--	📊
Research and Development	1	1	1	--	📊
Other Income Expenses	0	0	0	--	📊
EBITDA	-0	-1	-6	--	📊
EBITDA Growth (1Y)	--	-242.89%	-327.57%	--	📊
EBITDA Growth (5Y)	--	--	--	--	📊
EBITDA Growth (10Y)	--	--	--	--	📊
Depreciation and Amortization	0	0	0	--	📊
Operating Income	-1	-2	-6	--	📊
Operating Income Growth (1Y)	--	-177.30%	-290.13%	--	📊
Operating Income Growth (5Y)	--	--	--	--	📊
Operating Income Growth (10Y)	--	--	--	--	📊
Interest Expense	0	1	1	--	📊
Pre Tax Income	-1	-2	-7	--	📊
Tax Provision	0	-0	-0	--	📊
NET INCOME	-1	-2	-7	--	📊
Net Income Growth (1Y)	--	-151.80%	-214.89%	--	📊
Net Income Growth (5Y)	--	--	--	--	📊
Net Income Growth (10Y)	--	--	--	--	📊
Basic EPS	-0.04	-0.1	-0.26	--	📊
Diluted EPS	-0.04	-0.1	-0.26	--	📊
Basic Average Shares	20	21	26	--	📊
Diluted Average Shares	20	21	26	--	📊

Breakdown	2015 12/31	2016 12/31	2017 12/31	TTM
REVENUE	10	9	7	--	📊
Revenue Growth (1Y)	--	-6.56%	-26.25%	--	📊
Revenue Growth (5Y)	--	--	--	--	📊
Revenue Growth (10Y)	--	--	--	--	📊
Cost of Revenue	6	6	7	--	📊
Cost of Revenue Growth (1Y)	--	-7.01%	+19.27%	--	📊
Cost of Revenue Growth (5Y)	--	--	--	--	📊
Cost of Revenue Growth (10Y)	--	--	--	--	📊
Gross Profit	4	3	-0	--	📊
Gross Profit Growth (1Y)	--	-5.79%	-103.83%	--	📊
Gross Profit Growth (5Y)	--	--	--	--	📊
Gross Profit Growth (10Y)	--	--	--	--	📊
Operating Expenses	4	5	6	--	📊
Operating Expenses Growth (1Y)	--	+20.17%	+25.05%	--	📊
Operating Expenses Growth (5Y)	--	--	--	--	📊
Operating Expenses Growth (10Y)	--	--	--	--	📊
Sell General Administrative	3	4	5	--	📊
Research and Development	1	1	1	--	📊
Other Income Expenses	0	0	0	--	📊
EBITDA	-0	-1	-6	--	📊
EBITDA Growth (1Y)	--	-242.89%	-327.57%	--	📊
EBITDA Growth (5Y)	--	--	--	--	📊
EBITDA Growth (10Y)	--	--	--	--	📊
Depreciation and Amortization	0	0	0	--	📊
Operating Income	-1	-2	-6	--	📊
Operating Income Growth (1Y)	--	-177.30%	-290.13%	--	📊
Operating Income Growth (5Y)	--	--	--	--	📊
Operating Income Growth (10Y)	--	--	--	--	📊
Interest Expense	0	1	1	--	📊
Pre Tax Income	-1	-2	-7	--	📊
Tax Provision	0	-0	-0	--	📊
NET INCOME	-1	-2	-7	--	📊
Net Income Growth (1Y)	--	-151.80%	-214.89%	--	📊
Net Income Growth (5Y)	--	--	--	--	📊
Net Income Growth (10Y)	--	--	--	--	📊
Basic EPS	-0.04	-0.1	-0.26	--	📊
Diluted EPS	-0.04	-0.1	-0.26	--	📊
Basic Average Shares	20	21	26	--	📊
Diluted Average Shares	20	21	26	--	📊

Medite Cancer Diagnostics, Inc. - MDIT - Fundamentals - Financial Statements